PUVA‐induced lymphocyte apoptosis: Mechanism of action in psoriasis

Psoralen plus ultraviolet A (PUVA), utilizing oral 8‐methoxypsoralen (8‐MOP), is a widely utilized and effective treatment for psoriasis vulgaris. Previous studies have suggested that PUVA's mechanism of action in psoriasis is a result of its direct lymphotoxic effects. Trimethylpsoralen (TMP), a potentially safer compound, has been found to be effective in psoriasis during bath water delivery. In this study we examined the relative anti‐lymphocytic effects of TMP and 8‐MOP through both flow cytometry and tissue analysis on lesional skin during clinical treatment. Based on FACS analysis on phytohemagglutinin‐activated lymphocytes, we found TMP to be nearly 10,000 fold more lymphotoxic compared to 8‐MOP. In addition, lymphocytes treated with 8‐MOP or TMP with UVA displayed DNA degradation patterns typical of apoptotic cell death. These findings were consistent with our investigation of treated psoriatic skin, with virtual elimination of epidermal CD3+ T‐cells following bath water treatment with TMP or 8‐MOP. These results support the theory that the therapeutic effects of PUVA stem from its toxic effects on activated lymphocytes. If further investigation supports TMP's lack of carcinogenicity, this potent lymphotoxic treatment may prove to be one of the safest and most effective treatments for psoriasis.

[1]  J. Krueger,et al.  Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris. Evidence that epidermal immunocytes are direct therapeutic targets. , 1998, Archives of dermatology.

[2]  J. Travers,et al.  Lymphocyte activation in the pathogenesis of psoriasis. , 1997, The Journal of investigative dermatology.

[3]  R. Stern,et al.  Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. , 1997, The New England journal of medicine.

[4]  A. Hannuksela-Svahn,et al.  Trioxsalen Bath PUVA Does Not Increase the Risk of Squamous Cell Skin Carcinoma: A Joint Analysis of 1124 Swedish and Finnish Patients Followed Up for 10 Years , 1997 .

[5]  F. Gasparro,et al.  Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. , 1996, The Journal of investigative dermatology.

[6]  L. Staiano‐Coico,et al.  PUVA Treatment Selectively Induces a Cell Cycle Block and Subsequent Apoptosis in Human T‐Lymphocytes , 1996, Photochemistry and Photobiology.

[7]  A. Gottlieb,et al.  Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells , 1995, The Journal of experimental medicine.

[8]  James G. Krueger,et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.

[9]  A. Gottlieb,et al.  PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy , 1994, The Journal of experimental medicine.

[10]  R. Stern,et al.  The carcinogenic risk of treatments for severe psoriasis , 1994, Cancer.

[11]  B. Berne,et al.  Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report. , 1992, Archives of dermatology.

[12]  B. Berne,et al.  PUVA and cancer: a large-scale epidemiological study , 1991, The Lancet.

[13]  G. Piérard,et al.  Early dermato‐pathological signs during bath‐puva therapy , 1990, The Journal of pathology.

[14]  H. Roenigk,et al.  Long-term follow-up of skin cancer in the PUVA-48 cooperative study. , 1989, Archives of dermatology.

[15]  R. Stern,et al.  Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. , 1988, The Journal of investigative dermatology.

[16]  L. Koulu,et al.  Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. Comparison of 8-methoxypsoralen and trimethylpsoralen photosensitization. , 1988, Journal of the American Academy of Dermatology.

[17]  C. Cantor,et al.  Comparison of Synthetic Psoralen Derivatives and 8‐MOP in the Inhibition of Lymphocyte Proliferation a , 1985, Annals of the New York Academy of Sciences.

[18]  T. Reunala,et al.  Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis. , 1985, Acta dermato-venereologica.

[19]  B. Berne,et al.  Long-term safety of trioxsalen bath PUVA treatment: an 8-year follow-up of 149 psoriasis patients. , 1984, Photo-dermatology.

[20]  L. Koulu,et al.  Skin photosensitizing and Langerhans' cell depleting activity of topical (bath) PUVA therapy: comparison of trimethylpsoralen and 8-methoxypsoralen. , 1983, Acta dermato-venereologica.

[21]  J. Taskinen,et al.  Trioxsalen bath plus UVA treatment of psoriasis. Plasma concentration of the drug and clinical results. , 1981, Acta dermato-venereologica.

[22]  J. Karvonen,et al.  Trioxsalen bath plus UVA effective and safe in the treatment of psoriasis , 1978, The British journal of dermatology.

[23]  J. Alsins,et al.  Treatment of psoriasis with trioxsalen baths and dysprosium lamps. , 1976, Acta dermato-venereologica.

[24]  J. Parrish,et al.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. , 1974, The New England journal of medicine.